Clinical Study of Epalrestat in the Treatment of Diabetic Peripheral Neuropathy

Deng Yu-Lei,Wang Ying,Chen Sheng-Di
DOI: https://doi.org/10.3969/j.issn.1673-9523.2012.03.071
2006-01-01
Abstract:Objective To observe the efficacy and safety of epalrestat in the treatment of diabetic peripheral neuropathy. Methods 30 patients with diabetic peripheral neuropathy were randomly divided into 2 groups: epalrestat group(n=15) and mecobalamin group(n=15). The change of subjective symptom: neurological function and measuring results before and after treatment were compared between two groups. Result After four-week treatment, subjective symptoms were improved in both groups, and optimal improvement in subjective symptoms occurred after 12-week treatment, but there were no significant differences between two groups(P>0.05). Conclusion Epalrestat is safe and has similar effect on the treatment of diabetic peripheral neuropathy compared with mecobalamin.
What problem does this paper attempt to address?